These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 72471)

  • 21. Heterogeneity by cluster analysis techniques of Graves' patients typed for HLA DR and IgG heavy chain markers.
    Frecker MF; Preus M; Kozma L; Krasrits E; Stenszky V; Balazś C; Farid NR
    Mol Biol Med; 1986 Feb; 3(1):63-71. PubMed ID: 3083192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Graves' disease. Predominance of the DRw3 antigen (author's transl)].
    Allanic H; Fauchet R; Lorcy Y; Heim J; Guéguen M; Leguerrier AM; Genetet B
    Nouv Presse Med; 1980 Jun; 9(26):1823-6. PubMed ID: 6893077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of HLA antigen BW35 with severe Graves' ophthalmopathy.
    Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ; Sanford CA
    Invest Ophthalmol Vis Sci; 1983 Jan; 24(1):124-7. PubMed ID: 6600737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Japanese Graves' disease: association with HLA-Bw46.
    Naito S; Sasaki H; Arakawa K
    Endocrinol Jpn; 1987 Oct; 34(5):685-8. PubMed ID: 3436299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HLA-DR associations with Graves' disease in eastern Hungary.
    Stenszky V; Kozma L; Balazs C; Farid NR
    Clin Invest Med; 1983; 6(3):181-4. PubMed ID: 6580983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenetic markers in patients with Graves' disease.
    Schifferdecker E; Kühnl P; Schöffling K; Manfras B; Holzberger G; Spielmann W; Böhm BO
    Klin Wochenschr; 1991 Apr; 69(6):256-60. PubMed ID: 2038175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serological and molecular studies of HLA in Sardinian patients with Graves' disease.
    La Nasa G; Martino E; Carcassi C; Mulargia M; Floris L; Vacca A; Baldini G; Orrù S; Ledda A; Grasso L
    Dis Markers; 1991; 9(6):307-12. PubMed ID: 1823309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between HLA antigens and infectious agents in contributing towards the development of Graves' disease.
    Kraemer MH; Donadi EA; Tambascia MA; Magna LA; Prigenzi LS
    Immunol Invest; 1998; 27(1-2):17-29. PubMed ID: 9561915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid autoimmune disease in a large Newfoundland family: the influence of HLA.
    Farid NR; Barnard JM; Marshall WH; Woolfrey I; O'Driscoll RF
    J Clin Endocrinol Metab; 1977 Dec; 45(6):1165-72. PubMed ID: 579351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HLA antigens in autoimmune thyroid diseases.
    Arch Intern Med; 1978 Apr; 138(4):567-70. PubMed ID: 580355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The possible influence of HLA-A1, B8 antigens on the course of Graves' disease.
    Balázs CS; Stenszky V; Kozma L; Leövey A
    Biomedicine; 1978 Nov; 29(8):263-4. PubMed ID: 581746
    [No Abstract]   [Full Text] [Related]  

  • 32. Major histocompatibility complex (MHC) factors predisposing to and protecting against Graves' eye disease.
    Frecker M; Mercer G; Skanes VM; Farid NR
    Autoimmunity; 1988; 1(4):307-15. PubMed ID: 2979624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA-DW3 associated with coeliac disease.
    Keuning JJ; Peña AS; van Leeuwen A; van Hooff JP; va Rood JJ
    Lancet; 1976 Mar; 1(7958):506-8. PubMed ID: 55781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphism of the fourth component of complement in Graves' disease and type I diabetes mellitus.
    Skanes V; Larsen B; Sampson-Murphy L; Farid NR
    Clin Invest Med; 1985; 8(2):126-32. PubMed ID: 3869086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of subsets of patients with Graves' disease by cluster analysis.
    Stenszky V; Balázs C; Kozma L; Rochlitz S; Bear JC; Farid NR
    Clin Endocrinol (Oxf); 1983 Apr; 18(4):335-45. PubMed ID: 6603289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Class III alleles and high-risk MHC haplotypes in type I diabetes mellitus, Graves' disease and Hashimoto's thyroiditis.
    Skanes VM; Barnard J; Farid N; Marshall WH; Murphy L; Rideout D; Taylor R; Xidos G; Larsen B
    Mol Biol Med; 1986 Apr; 3(2):143-57. PubMed ID: 3461234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA class I and II antigens in South African blacks with Graves' disease.
    Omar MA; Hammond MG; Desai RK; Motala AA; Aboo N; Seedat MA
    Clin Immunol Immunopathol; 1990 Jan; 54(1):98-102. PubMed ID: 2293909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of HLA antigens with thyrotoxic Graves' disease and periodic paralysis in Hong Kong Chinese.
    Hawkins BR; Ma JT; Lam KS; Wang CC; Yeung RT
    Clin Endocrinol (Oxf); 1985 Sep; 23(3):245-52. PubMed ID: 3865750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Graves' disease: immunological and immunogenetic indicators of relapse.
    de Bruin TW; Bolk JH; Bussemaker JK; Stijnen T; Schreuder GM; de Vries RR; van der Heide D
    Br Med J (Clin Res Ed); 1988 May; 296(6632):1292-5. PubMed ID: 3133054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA immunogenetic heterogeneity in black American patients with Graves' disease.
    Sridama V; Hara Y; Fauchet R; DeGroot LJ
    Arch Intern Med; 1987 Feb; 147(2):229-31. PubMed ID: 3468887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.